GLTO Galecto, Inc. Stock Quote

GLTO [NASD]

Index	-	P/E	-	EPS (ttm)	-1.70	Insider Own	11.42%	Shs Outstand	25.26M	Perf Week	14.96%
Market Cap	202.07M	Forward P/E	-	EPS next Y	-2.12	Insider Trans	0.00%	Shs Float	22.38M	Perf Month	11.53%
Income	-42.50M	PEG	-	EPS next Q	-0.54	Inst Own	60.20%	Short Float	0.62%	Perf Quarter	-40.57%
Sales	-	P/S	-	EPS this Y	19.40%	Inst Trans	5.29%	Short Ratio	0.30	Perf Half Y	-60.77%
Book/sh	6.04	P/B	0.93	EPS next Y	7.40%	ROA	-	Target Price	-	Perf Year	-
Cash/sh	3.06	P/C	1.83	EPS next 5Y	47.60%	ROE	-	52W Range	4.50 - 17.99	Perf YTD	-55.16%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-70.04%	Beta	-
Dividend %	-	Quick Ratio	21.10	Sales past 5Y	-	Gross Margin	-	52W Low	19.71%	ATR	1.18
Employees	28	Current Ratio	21.10	Sales Q/Q	-	Oper. Margin	-	RSI (14)	49.88	Volatility	56.63% 18.14%
Optionable	No	Debt/Eq	0.00	EPS Q/Q	-128.90%	Profit Margin	-	Rel Volume	5.69	Prev Close	5.61
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Mar 29 BMO	Payout	-	Avg Volume	461.01K	Price	5.39
Recom	1.20	SMA20	5.33%	SMA50	-2.10%	SMA200	-47.58%	Volume	1,784,620	Change	-3.94%

Apr-26-21

Resumed

Credit Suisse

Outperform

$12

Nov-23-20

Initiated

SVB Leerink

Outperform

$27

Nov-23-20

Initiated

Credit Suisse

Outperform

$29

Nov-23-20

Initiated

BofA Securities

Buy

$21

Jun-10-21 03:31PM	Orphazyme stock's rocket ride leads to 20 volatility halts, Galecto stock halted 7 times MarketWatch +60.00%
Jun-02-21 08:00AM	Galecto Hosting Expert Perspectives Webinar on the Current Myelofibrosis Treatment Landscape and Potential Future Treatments GlobeNewswire
May-11-21 08:00AM	Galecto Appoints Garrett Winslow as General Counsel GlobeNewswire
May-06-21 08:00AM	Galecto to Present at Upcoming Investor Conferences and Host Myelofibrosis Key Opinion Leader Event GlobeNewswire
May-04-21 08:30AM	Galecto Reports First Quarter Financial Results and Provides a Corporate Update GlobeNewswire
Apr-29-21 05:49AM	Do Institutions Own Galecto, Inc. (NASDAQ:GLTO) Shares? Simply Wall St.
Apr-19-21 06:38AM	Galecto (GLTO) Enters Oversold Territory Zacks
Apr-15-21 08:00AM	Galectin-3 has a key role in Gastric Cancer GlobeNewswire
Mar-29-21 08:30AM	Galecto Reports Financial Results for the Year Ended December 31, 2020 and Provides a Corporate Update GlobeNewswire
Mar-23-21 10:26AM	UPDATE: Galecto Hosting Expert Perspective Panel on the Evolving Treatment Landscape for Idiopathic Pulmonary Fibrosis and Potential for GB0139 GlobeNewswire
08:30AM	Galecto Hosting Expert Perspective Panel on the Evolving Treatment Landscape for Idiopathic Pulmonary Fibrosis and Potential for GB0139 GlobeNewswire
Mar-15-21 07:30AM	Galecto Announces Outcome of Data Safety Monitoring Board Interim Review of Phase 2b GALACTIC-1 Study of GB0139 for Idiopathic Pulmonary Fibrosis: DSMB Recommends Study to Continue with Modifications GlobeNewswire -5.61%
Feb-09-21 08:00AM	Galecto to Present at Upcoming Investor Conferences GlobeNewswire
Jan-29-21 01:33AM	We Think Galecto (NASDAQ:GLTO) Can Afford To Drive Business Growth Simply Wall St.
Jan-08-21 08:00AM	Galecto Appoints Anne Prener to its Board of Directors GlobeNewswire
Jan-04-21 04:01PM	Galecto to Take Part in Two Panel Discussions at the LifeSci Partners 10th Annual Healthcare Corporate Access Event GlobeNewswire
Dec-11-20 08:06AM	Galecto Reports Third Quarter 2020 Operating & Financial Results and Provides a Corporate Update GlobeNewswire
Nov-30-20 08:00AM	Galecto Publishes GB0139 Phase 2a Idiopathic Pulmonary Fibrosis (IPF) Results in European Respiratory Journal, Showing Marked Impact on Several IPF Biomarkers GlobeNewswire
Nov-23-20 04:01PM	Galecto Appoints Experienced Healthcare Executive Jayson Dallas to Board of Directors GlobeNewswire
Oct-29-20 01:28PM	Leslies Pops 30%, Allegro Jumps 41% in IPO Debuts Barrons.com
Oct-28-20 09:10PM	Galecto Announces Pricing of Initial Public Offering GlobeNewswire

Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a life-threatening progressive fibrotic disease of the lung. Its products also comprise GB2064, which is in Phase I/IIa for the treatment of myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase I/IIa for the treatment of cancer and fibrosis. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience